Richard J. Benjamin - Mar 12, 2022 Form 4 Insider Report for CERUS CORP (CERS)

Role
Chief Medical Officer
Signature
Richard J. Benjamin, by Chrystal Menard, attorney-in-fact
Stock symbol
CERS
Transactions as of
Mar 12, 2022
Transactions value $
-$152,735
Form type
4
Date filed
3/15/2022, 09:50 PM
Previous filing
Mar 3, 2022
Next filing
Aug 11, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CERS Common Stock Options Exercise +45K +35.01% 174K Mar 12, 2022 Direct F1
transaction CERS Common Stock Sale -$81.4K -16.2K -9.31% $5.04 157K Mar 14, 2022 Direct F2, F3
transaction CERS Common Stock Options Exercise +22.8K +14.47% 180K Mar 12, 2022 Direct F1
transaction CERS Common Stock Sale -$41.2K -8.17K -4.54% $5.04 172K Mar 14, 2022 Direct F2, F3
transaction CERS Common Stock Options Exercise +16.7K +9.69% 189K Mar 12, 2022 Direct F1
transaction CERS Common Stock Sale -$30.1K -5.98K -3.17% $5.04 183K Mar 14, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CERS Restricted Stock Unit Options Exercise -45K -100% 0 Mar 12, 2022 Common Stock 45K Direct F1, F4, F5
transaction CERS Restricted Stock Unit Options Exercise -22.8K -49.25% 23.5K Mar 12, 2022 Common Stock 22.8K Direct F1, F5, F6
transaction CERS Restricted Stock Unit Options Exercise -16.7K -33.33% 33.3K Mar 12, 2022 Common Stock 16.7K Direct F1, F5, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one (1) share of Cerus Common Stock.
F2 Represents shares sold pursuant to an instruction intended to comply with the requirements of Rule 10b5-1 that was elected by the Reporting Person on the date of grant to cover statutory tax withholding obligations and corresponding brokerage fee in connection with the vesting of the restricted stock units listed in Table II and does not represent a discretionary sale by the reporting person.
F3 This transaction was executed pursuant to a 10b5-1 plan. The reported price in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.871 to $5.22 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the aforementioned range set forth.
F4 The restricted stock unit vests 33% on March 12, 2020, 33% on March 12, 2021 and 34% on March 12, 2022.
F5 Not applicable.
F6 The restricted stock unit vests 33% on March 12, 2021, 33% on March 12, 2022 and 34% on March 12, 2023.
F7 The restricted stock unit vests in three equal annual installments beginning on March 12, 2022.